EDIT
Editas Medicine
Follow Write Post
EDIT Price Today by TradingView
Add A Trade Add A Catalyst Event
EDIT - Editas Medicine 23:08 PM - Sep 04 2021
by: Maverick

EDIT - Editas Medicine - DD - September 2021

EDIT - Editas Medicine

 Price: 63.50 (8/31/21)
Original entry: 49
OS: 68M
Float: 58M
Cash: $580M (about 40 months worth)

What they do


Editas Medicine is a leading genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of medicines for people living with serious diseases around the world.

History: https://en.wikipedia.org/wiki/Editas_Medicine (including funding from Bill Gates)


Chart

The run to 100 in December 2020 was on the back of EDIT filing for IND for EDIT-301 (focused on sickle cell disease)

It gave up all of that run, going all the way back to 30.

Things started ticking up again in June 2021 after sharing preclinical data on EDIT301 (June 11).  That took it to 60.  Then it dropped back down to 40 before it started the current run we’re on, which kicked off with the August 4th Business/Pipeline Update, which had several catalyst events in it - ir.editasmedicine.com/news-rel...


Upcoming catalysts

September 27 - Initial clinical data for EDIT-101 (Leber Congenital Amaurosis 10 (LCA10), adult cohort, low and mid-dose).  The mission here is to restore vision in adults and children. 

EOY - dosing on EDIT-301 ( sickle cell disease, currently in patient screening).  Preclinical data suggests this could be best in class treatment.

EOY - EDIT-301 IND filing - expanding indication to Beta-Thalassemia


Thoughts

As long as gene-editing stays in favor, this should be a good one long-term, it’s still undervalued in comparison to its peers.  EDIT has all-star talent on their team and are leveraging the latest CRISPR technology. https://www.editasmedicine.com/crispr-gene-editing/

They will likely just keep filing for more indications as they progress, which will only boost their value.

Trades

I picked this up originally at 49.  Sold at 54.  Didn’t realize what I had.  Then started scooping it up anytime it dipped below 60.  I’m now done trading (and buying) and holding for the 9/27 EDIT-101 data event.  I’ll be back for the end of the year IND and dosing, most likely.
Read More
1
0
EDIT - Editas Medicine 22:35 PM - Sep 04 2021
by: Maverick

This one hit 73 on Thursday. 🚀
Read More
0
0
EDIT - Editas Medicine 22:45 PM - Aug 22 2021
by: Maverick

63 in after hours on Friday.  Should be a good few weeks coming up for EDIT.
Read More
0
0
EDIT - Editas Medicine 22:45 PM - Aug 22 2021
by: Maverick

Editas Medicine Presents Data on New SLEEK Gene Editing Technology



globenewswire.com/news-release...

“We find the new gene editing SLEEK technology to have immense potential, as it enables nearly 100 percent knock-in of functional transgene cargos at specific locations in the genome, which we believe to be the highest in the gene editing field across multiple cell types. We believe that this novel technology has broad applications and may result in substantially improved gene edited cell medicines, including for novel CAR-T and CAR-NK cell therapies,” said Mark S. Shearman, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine. “We believe SLEEK is an optimal approach to achieve highly efficient multi-transgene knock-in for the next generation of cell therapy medicines, and we are leveraging this technology across many oncology programs, including for treatment of a variety of solid tumors.”
Read More
0
0
EDIT - Editas Medicine 23:45 PM - Aug 08 2021
by: Maverick

I picked this one up alongside $CRSP last week.

I'll have some due diligence coming on both.

This is a new space for me, so it should be fun.
Read More
0
0
Mentions: CRSP

Editas Medicine - EDIT

Total Followers: 1
EDIT Chart by TradingView
Follow
Latest EDIT News
Link Copied to Clipboard!